Shirley Bleak
Family · Salt Lake City, UTNPI 1124197512
Payments from drug & device makers
Across 72 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$471
- AstraZeneca$271
- Pfizer$206
- Seagen Inc.$198
- Pharmacyclics LLC, An Abbvie Company$122
- GSK$113
- plus $778 from 22 others
What the payments were for
- Food & beverage$1,66177%
- Education$49723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $471 |
| AstraZeneca | 10 | $271 |
| Pfizer | 6 | $206 |
| Seagen Inc. | 2 | $198 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $122 |
| GSK | 6 | $113 |
| Daiichi Sankyo Inc. | 5 | $107 |
| EMD Serono, Inc. | 4 | $96 |
| AbbVie | 2 | $48 |
| Eisai Inc. | 2 | $47 |
| Genmab U.S., Inc. | 2 | $43 |
| Gilead | 2 | $42 |
| Novartis | 2 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Astellas Pharma US Inc | 2 | $32 |
| Sanofi | 1 | $30 |
| Amgen | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Novocure Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,158 in reported general payments places this provider in the 80th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $263 |
| Hydroxyurea | 11 | $195 |
| Prochlorperazine Maleate | 14 | $151 |
Paid to pharmacies, not to this prescriber.
Other family in Salt Lake City
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Kacie Doyle-DelgadoSalt Lake City$80K
- Melonie ThompsonSalt Lake City$45K
- Michelle LitchmanSalt Lake City$44K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.